Annuncio pubblicitario
Italia markets close in 50 minutes
  • FTSE MIB

    33.271,76
    -43,92 (-0,13%)
     
  • Dow Jones

    38.834,86
    +56,76 (+0,15%)
     
  • Nasdaq

    17.862,23
    +5,21 (+0,03%)
     
  • Nikkei 225

    38.570,76
    +88,65 (+0,23%)
     
  • Petrolio

    81,77
    +0,20 (+0,25%)
     
  • Bitcoin EUR

    60.406,85
    -330,61 (-0,54%)
     
  • CMC Crypto 200

    1.379,46
    +41,71 (+3,12%)
     
  • Oro

    2.342,10
    -4,80 (-0,20%)
     
  • EUR/USD

    1,0749
    +0,0006 (+0,05%)
     
  • S&P 500

    5.487,03
    +13,80 (+0,25%)
     
  • HANG SENG

    18.430,39
    +514,84 (+2,87%)
     
  • Euro Stoxx 50

    4.892,11
    -23,36 (-0,48%)
     
  • EUR/GBP

    0,8444
    -0,0004 (-0,05%)
     
  • EUR/CHF

    0,9501
    +0,0009 (+0,09%)
     
  • EUR/CAD

    1,4722
    -0,0009 (-0,06%)
     

Abeona Therapeutics Announces Date Change for First Quarter 2023 Portfolio Update Conference Call to May 24, 2023

Abeona Therapeutics Inc.
Abeona Therapeutics Inc.

CLEVELAND, May 22, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has changed the date of its previously announced First Quarter 2023 Portfolio Update conference call and webcast to Wednesday, May 24, 2023, at 8:30 a.m. ET. The call was previously scheduled for Tuesday, May 23, 2023, at 8:30 a.m. ET.

To access the call, dial 888-506-0062 (U.S. toll-free) or 973-528-0011 (international) and Entry Code: 885338 five minutes prior to the start of the call. A live, listen-only webcast and archived replay of the call can be accessed on the Investors & Media section of Abeona’s website at www.abeonatherapeutics.com. The archived webcast replay will be available for 30 days following the call.

About Abeona Therapeutics
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s lead clinical program is EB-101, its investigational autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa. The Company’s development portfolio also features AAV-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Abeona’s fully integrated cell and gene therapy cGMP manufacturing facility produces EB-101 for the pivotal Phase 3 VIITAL™ study and is capable of clinical and potential commercial production of AAV-based gene therapies. For more information, visit www.abeonatherapeutics.com.

ANNUNCIO PUBBLICITARIO

Forward-Looking Statements
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted to identify forward-looking statements by such terminology as “may,” “will,” “believe,” “anticipate,” “expect,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to, the timing and outcome of our Biologics License Application submission to the FDA for EB-101; continued interest in our rare disease portfolio; our ability to enroll patients in clinical trials; the outcome of future meetings with the FDA or other regulatory agencies, including those relating to preclinical programs; the ability to achieve or obtain necessary regulatory approvals; the impact of any changes in the financial markets and global economic conditions; risks associated with data analysis and reporting; and other risks disclosed in the Company’s most recent Annual Report on Form 10-K and subsequent periodic reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to revise the forward-looking statements or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.

CONTACT: Investor and Media Contact: Greg Gin VP, Investor Relations and Corporate Communications Abeona Therapeutics ir@abeonatherapeutics.com